Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (Q24244894)

Cochrane Database of Systematic Reviews

Europe PubMed Central

title

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis (English)

0 references

main subject

Pseudomonas aeruginosa

0 references

cystic fibrosis

0 references

author name string

Damian M Wood

series ordinal

1

0 references

Alan R Smyth

series ordinal

2

0 references

publication date

25 January 2006

0 references

published in

0 references

cites work

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Randomized trials stopped early for benefit: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Prophylactic anti-staphylococcal antibiotics for cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: correlations between anti-Pseudomonas aeruginosa antibody levels and pulmonary function

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

The changing epidemiology of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Cultures of thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Management of pulmonary disease in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Risk factors for Pseudomonas aeruginosa colonization in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Treatment of pseudomonas aeruginosa colonisation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021

Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004197.PUB2

7 January 2021